FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283700531> ?p ?o ?g. }

• W4283700531 endingPage "1225" @default.
• W4283700531 startingPage "1225.1" @default.
• W4283700531 abstract "Background Osteoporosis is one of the main comorbidity of RA and leads to an increased risk for fragility fractures, which further impair functional ability, quality of life, and life expectancy. The influence of this condition on the maintenance and survival of biotherapies has rarely been studied. Objectives To assess the influence of osteoporosis on efficacy, tolerance, and biologic drugs survival. Methods We conducted a cross-sectional and observational study. Files of patients with RA on biologics drugs (archived from the files of patients on the National Health Insurance Fund of Tunis) were studied. Epidemiological characteristics such as age, sex, and comorbidities, were collected. All patients had a bone mineral density measurement. The patients were divided into two groups (a group with G1 osteoporosis and a group without osteoporosis G2). The therapeutic maintenance rate at 12, 24, 36, and 48 months as well as the biologic survival were analyzed using Kaplan-Meier survival curves and compared using the Log-Rank test. Results Three hundred and seventy-four files were selected. The average age of our cohort was 55±12.54 years [20-90]. A female predominance was noted with a sex ratio M/F=0.147. The average duration of RA was 11.7±6.76 years [2-41]. Osteoporosis was observed in 78 patients (20.9%). First biogics prescription was: tocilizumab 6% and rituximab 7%, etanercept 54%, adalimumab 14%, certolizumab pegol 13%, infliximab 6%.The maintenance of the first biotherapy was 40.53 [35.64-45.43] in G1 and 41.44 [39.01-43.86] in G2. The biologic survival curve study did not find any significant difference between the two group p= 0.598. The presence of osteoporosis would increase the risk of stopping biotherapy without being a statistically significant factor (HR = 1.109, p = 0.602) The therapeutic maintenance of the 1st biotherapy, in the presence of osteoporosis, was on average 40.53 months [35.64-45.43]. Conclusion Osteoporosis has not hitherto been retained as a determining factor in therapeutic maintenance (1), as was indeed the case in our study. Nevertheless, screening and early management of osteoporosis are necessary since it alone constitutes a risk factor for mortality. References [1]Leon L, Rodriguez-Rodriguez L, Rosales Z, Gomez A, Lamas JR, Pato E, et al. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol. 2016;45(6):456-60. Disclosure of Interests None declared" @default.
• W4283700531 created "2022-06-30" @default.
• W4283700531 creator A5015429334 @default.
• W4283700531 creator A5019089170 @default.
• W4283700531 creator A5051235646 @default.
• W4283700531 creator A5051714447 @default.
• W4283700531 creator A5068784630 @default.
• W4283700531 creator A5071175515 @default.
• W4283700531 creator A5073227730 @default.
• W4283700531 creator A5075615387 @default.
• W4283700531 date "2022-05-23" @default.
• W4283700531 modified "2023-09-26" @default.
• W4283700531 title "AB0191 OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS: IMPACT ON BIOLOGIC DRUGS TOLERANCE AND SURVIVAL" @default.
• W4283700531 doi "https://doi.org/10.1136/annrheumdis-2022-eular.3225" @default.
• W4283700531 hasPublicationYear "2022" @default.
• W4283700531 type Work @default.
• W4283700531 citedByCount "0" @default.
• W4283700531 crossrefType "journal-article" @default.
• W4283700531 hasAuthorship W4283700531A5015429334 @default.
• W4283700531 hasAuthorship W4283700531A5019089170 @default.
• W4283700531 hasAuthorship W4283700531A5051235646 @default.
• W4283700531 hasAuthorship W4283700531A5051714447 @default.
• W4283700531 hasAuthorship W4283700531A5068784630 @default.
• W4283700531 hasAuthorship W4283700531A5071175515 @default.
• W4283700531 hasAuthorship W4283700531A5073227730 @default.
• W4283700531 hasAuthorship W4283700531A5075615387 @default.
• W4283700531 hasBestOaLocation W42837005311 @default.
• W4283700531 hasConcept C126322002 @default.
• W4283700531 hasConcept C207103383 @default.
• W4283700531 hasConcept C2776541429 @default.
• W4283700531 hasConcept C2776886416 @default.
• W4283700531 hasConcept C2777138892 @default.
• W4283700531 hasConcept C2777178219 @default.
• W4283700531 hasConcept C2777226972 @default.
• W4283700531 hasConcept C2777575956 @default.
• W4283700531 hasConcept C2779134260 @default.
• W4283700531 hasConcept C2779338263 @default.
• W4283700531 hasConcept C2779605438 @default.
• W4283700531 hasConcept C2780132546 @default.
• W4283700531 hasConcept C2780653079 @default.
• W4283700531 hasConcept C44249647 @default.
• W4283700531 hasConcept C71924100 @default.
• W4283700531 hasConceptScore W4283700531C126322002 @default.
• W4283700531 hasConceptScore W4283700531C207103383 @default.
• W4283700531 hasConceptScore W4283700531C2776541429 @default.
• W4283700531 hasConceptScore W4283700531C2776886416 @default.
• W4283700531 hasConceptScore W4283700531C2777138892 @default.
• W4283700531 hasConceptScore W4283700531C2777178219 @default.
• W4283700531 hasConceptScore W4283700531C2777226972 @default.
• W4283700531 hasConceptScore W4283700531C2777575956 @default.
• W4283700531 hasConceptScore W4283700531C2779134260 @default.
• W4283700531 hasConceptScore W4283700531C2779338263 @default.
• W4283700531 hasConceptScore W4283700531C2779605438 @default.
• W4283700531 hasConceptScore W4283700531C2780132546 @default.
• W4283700531 hasConceptScore W4283700531C2780653079 @default.
• W4283700531 hasConceptScore W4283700531C44249647 @default.
• W4283700531 hasConceptScore W4283700531C71924100 @default.
• W4283700531 hasIssue "Suppl 1" @default.
• W4283700531 hasLocation W42837005311 @default.
• W4283700531 hasOpenAccess W4283700531 @default.
• W4283700531 hasPrimaryLocation W42837005311 @default.
• W4283700531 hasRelatedWork W11739056 @default.
• W4283700531 hasRelatedWork W2075390633 @default.
• W4283700531 hasRelatedWork W2135289971 @default.
• W4283700531 hasRelatedWork W2238463541 @default.
• W4283700531 hasRelatedWork W2318113264 @default.
• W4283700531 hasRelatedWork W2553314347 @default.
• W4283700531 hasRelatedWork W2555960257 @default.
• W4283700531 hasRelatedWork W3048744826 @default.
• W4283700531 hasRelatedWork W4283700531 @default.
• W4283700531 hasRelatedWork W4310797979 @default.
• W4283700531 hasVolume "81" @default.
• W4283700531 isParatext "false" @default.
• W4283700531 isRetracted "false" @default.
• W4283700531 workType "article" @default.